Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy

PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer

Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989

Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review

Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay‐Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,320

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157

Pembrolizumab versus Ipilimumab in Advanced Melanoma

Robert, C., Schachter, J., Long, G. V., Arance, A., Grob, J. J., Mortier, L., Daud, A., Carlino, M. S., McNeil, C., Lotem, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503093 · Cited by 5,887

Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma

Robert, C., Thomas, L., Bondarenko, I., O'Day, S., Weber, J., Garbe, C., Lebbe, C., Baurain, J.-F., Testori, A., Grob, J.-J., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1104621 · Cited by 4,496

Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

Hamid, O., Robert, C., DAUD, A. I., Hodi, F. S., Hwu, W., Kefford, R. F., Wolchok, J. D., Hersey, P., Joseph, R. W., Weber, J. S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305133 · Cited by 3,427

Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4

Tivol, E. A., Borriello, F., Schweitzer, A. N., Lynch, W. P., Bluestone, J. A., & Sharpe, A. H. (1995) · Immunity · doi:10.1016/1074-7613(95)90125-6 · Cited by 2,914

Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab

Topalian, S. L., Sznol, M., McDermott, D. F., Kluger, H. M., Carvajal, R. D., Sharfman, W. H., Brahmer, J. R., Lawrence, D. P., Atkins, M. B., Powderly, J. D., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.53.0105 · Cited by 2,222

Autoimmune Dilated Cardiomyopathy in PD-1 Receptor-Deficient Mice

Nishimura, H., Okazaki, T., Tanaka, Y., Nakatani, K., Hara, M., Matsumori, A., Sasayama, S., Mizoguchi, A., Hiai, H., Minato, N., et al. (2001) · Science · doi:10.1126/science.291.5502.319 · Cited by 1,868

Immune checkpoint proteins: exploring their therapeutic potential to regulate atherosclerosis

Foks, A. C., & Kuiper, J. (2017) · British Journal of Pharmacology · doi:10.1111/bph.13802 · Cited by 59

Cardiotoxicity Induced by Immune Checkpoint Inhibitors: A Pharmacovigilance Study From 2014 to 2019 Based on FAERS

Chen, C., Chen, T., Liang, J., Guo, X., Xu, J., Zheng, Y., Guo, Z., Chi, L., Wei, L., Chen, X., et al. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.616505 · Cited by 58

Cardio-Oncology: A Myriad of Relationships Between Cardiovascular Disease and Cancer

Wang, Y., Wang, Y., Han, X., Sun, J. H., Li, C., Adhikari, B. K., Zhang, J., Miao, X., & Chen, Z. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.727487 · Cited by 63

Mesoporous Silica Nanoparticles as an Ideal Platform for Cancer Immunotherapy: Recent Advances and Future Directions.

Godakhindi, V., Tarannum, M., Dam, S. K., & Vivero-Escoto, J. L. (2024) · Advanced Healthcare Materials · doi:10.1002/adhm.202400323 · Cited by 65

Harnessing in situ glutathione for effective ROS generation and tumor suppression via nanohybrid-mediated catabolism dynamic therapy

Peng, S., Liu, X., Chen, Q., Yu, Y., Liu, M., & Zhang, X. (2021) · Biomaterials · doi:10.1016/j.biomaterials.2021.121358 · Cited by 58

A Century of Radiation Therapy and Adaptive Immunity

Schaue, D. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00431 · Cited by 57

Pericardial effusion under nivolumab: case-reports and review of the literature

Saade, A., Mansuet‐Lupo, A., Arrondeau, J., Thibault, C., Mirabel, M., Goldwasser, F., Oudard, S. M., & Weiss, L. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0760-4 · Cited by 57

Cardiotoxic mechanisms of cancer immunotherapy – A systematic review

Lobenwein, D., Kocher, F., Dobner, S., Gollmann‐Tepeköylü, C., & Holfeld, J. (2020) · International Journal of Cardiology · doi:10.1016/j.ijcard.2020.08.033 · Cited by 59

PD-1/PDL-1 Inhibitors and Cardiotoxicity; Molecular, Etiological and Management Outlines

Safi, M., Ahmed, H., Al‐Azab, M., Xia, Y., Shan, X., Alradhi, M., Al-Danakh, A., Shopit, A., & Liu, J. (2020) · Journal of Advanced Research · doi:10.1016/j.jare.2020.09.006 · Cited by 57

Cardiac Toxicity in Patients Treated With Immune Checkpoint Inhibitors

Tocchetti, C. G., Galdiero, M. R., & Varricchi, G. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.02.038 · Cited by 56

Immune checkpoint inhibitors associated cardiovascular immune-related adverse events

Jo, W., Won, T., Daoud, A., & Čiháková, D. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1340373 · Cited by 55

Myocarditis with tremelimumab plus durvalumab combination therapy for endometrial cancer: A case report

Mahmood, S., Chen, C. L., Shapnik, N., Krishnan, U., Singh, H. S., & Makker, V. (2018) · Gynecologic Oncology Reports · doi:10.1016/j.gore.2018.05.014 · Cited by 55

Rational discovery of dual-indication multi-target PDE/Kinase inhibitor for precision anti-cancer therapy using structural systems pharmacology

Lim, H., He, D., Qiu, Y., Krawczuk, P., Sun, X., & Xie, L. (2019) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1006619 · Cited by 54

Ten-year cardiovascular risk among cancer survivors: The National Health and Nutrition Examination Survey

Zhang, X., Pawlikowski, M., Olivo‐Marston, S., Williams, K. P., Bower, J. K., & Felix, A. S. (2021) · PLoS ONE · doi:10.1371/journal.pone.0247919 · Cited by 58

Nivolumab-Induced Myocarditis Concomitant with Myasthenia Gravis

Fukasawa, Y., Sasaki, K., Natsume, M., Nakashima, M., Ota, S., Watanabe, K., Takahashi, Y., Kondo, F., Kozuma, K., & Seki, N. (2017) · Case Reports in Oncology · doi:10.1159/000479958 · Cited by 54

A closer look at immune-mediated myocarditis in the era of combined checkpoint blockade and targeted therapies

Guo, C. W., Alexander, M., Dib, Y., Lau, P. K. H., Weppler, A. M., Au‐Yeung, G., Lee, B., Khoo, C. C. H., Mooney, D., Joshi, S. B., et al. (2019) · European Journal of Cancer · doi:10.1016/j.ejca.2019.09.009 · Cited by 55

Optimizing Cardiovascular Health in Patients With Cancer: A Practical Review of Risk Assessment, Monitoring, and Prevention of Cancer Treatment–Related Cardiovascular Toxicity

Dent, S. F., Kikuchi, R., Kondapalli, L., Ismail-Khan, R. R., Brezden‐Masley, C., Barac, A., & Fradley, M. G. (2020) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_286019 · Cited by 59

Left Ventricular Dysfunction in Cancer Treatment

Kenigsberg, B. B., Wellstein, A., & Barac, A. (2017) · JACC Heart Failure · doi:10.1016/j.jchf.2017.08.024 · Cited by 52

Inflammatory markers in autoimmunity induced by checkpoint inhibitors

Husain, B., Kirchberger, M. C., Erdmann, M., Schüpferling, S., Abolhassani, A.-R., Fröhlich, W., Berking, C., & Heinzerling, L. (2021) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-021-03550-5 · Cited by 56

Myocarditis occurrence with cancer immunotherapy across indications in clinical trial and post-marketing data

Makunts, T., Saunders, I. M., Cohen, I. V., Li, M., Moumedjian, T., Issa, M. A., Burkhart, K., Lee, P., Patel, S. P., & Abagyan, R. A. (2021) · Scientific Reports · doi:10.1038/s41598-021-96467-5 · Cited by 56

Update on cardio-oncology: Novel cancer therapeutics and associated cardiotoxicities

Guha, A., Armanious, M. A., & Fradley, M. G. (2018) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2018.06.001 · Cited by 54

Cancer immune checkpoint blockade therapy and its associated autoimmune cardiotoxicity

Zhang, J.-C., Chen, W., Alvarez, J. B., Jia, K. Q., Shi, L., Wang, Q., Zou, N., He, K., & Zhu, H. (2018) · Acta Pharmacologica Sinica · doi:10.1038/s41401-018-0062-2 · Cited by 54

Management of Cardiac Toxicity Induced by Chemotherapy

Trapani, D., Zagami, P., Nicolò, E., Pravettoni, G., & Curigliano, G. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9092885 · Cited by 57

Anticancer Drug-Induced Cardiotoxicity: Insights and Pharmacogenetics

Adhikari, A., Asdaq, S. M. B., Hawaj, M. A. A., Chakraborty, M., Thapa, G., Bhuyan, N. R., Imran, M., Alshammari, M. K., Alshehri, M. M., Harshan, A. A., et al. (2021) · Pharmaceuticals · doi:10.3390/ph14100970 · Cited by 54

Nanobodies for Medical Imaging: About Ready for Prime Time?

Berland, L., Kim, L., Abousaway, O., Mines, A., Mishra, S., Clark, L. M., Hofman, P. M., & Rashidian, M. (2021) · Biomolecules · doi:10.3390/biom11050637 · Cited by 56

Immune checkpoints in cardiac physiology and pathology: therapeutic targets for heart failure

Gergely, T. G., Drobni, Z. D., Kallikourdis, M., Zhu, H., Meijers, W. C., Neilan, T. G., Rassaf, T., Ferdinandy, P., & Varga, Z. V. (2024) · Nature Reviews Cardiology · doi:10.1038/s41569-023-00986-9 · Cited by 57

Myocarditis with Immune Checkpoint Blockade

Moslehi, J. J., Johnson, D. B., & Sosman, J. A. (2017) · New England Journal of Medicine · doi:10.1056/nejmc1615251 · Cited by 52

Heart Failure and Cancer: Mechanisms of Old and New Cardiotoxic Drugs in Cancer Patients

Cuomo, A., Rodolico, A., Galdieri, A., Russo, M., Campi, G., Franco, R., Bruno, D., Aran, L., Carannante, A., Attanasio, U., et al. (2019) · Cardiac failure review · doi:10.15420/cfr.2018.32.2 · Cited by 54

Autoimmune Myocarditis, Old Dogs and New Tricks.

Won, T., Song, E. J., Kalinoski, H. M., Moslehi, J. J., & Čiháková, D. (2024) · Circulation Research · doi:10.1161/circresaha.124.323816 · Cited by 51

Mechanisms shared between cancer, heart failure, and targeted anti-cancer therapies

de Wit, S., Glen, C., de Boer, R. A., & Lang, N. N. (2022) · Cardiovascular Research · doi:10.1093/cvr/cvac132 · Cited by 54

Insights into Drug Cardiotoxicity from Biological and Chemical Data: The First Public Classifiers for FDA Drug-Induced Cardiotoxicity Rank

Seal, S., Spjuth, O., Hosseini-Gerami, L., García-Ortegón, M., Singh, S., Bender, A., & Carpenter, A. E. (2024) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.3c01834 · Cited by 55

Autoimmunity in Acute Myocarditis: How Immunopathogenesis Steers New Directions for Diagnosis and Treatment

Bruestle, K., Hackner, K., Kreye, G., & Heidecker, B. (2020) · Current Cardiology Reports · doi:10.1007/s11886-020-01278-1 · Cited by 53

Characterization of Immune Checkpoint Inhibitor-Related Cardiotoxicity in Lung Cancer Patients From a Rural Setting

Moey, M., Tomdio, A. N., McCallen, J., Vaughan, L., O'Brien, K. F., Naqash, A. R., Cherry, C. R., Walker, P. R., & Carabello, B. A. (2020) · JACC CardioOncology · doi:10.1016/j.jaccao.2020.07.005 · Cited by 48

Cardiovascular disease-specific mortality in 270,618 patients with non-small cell lung cancer

Sun, J., Zhang, Z., Qu, Q., Wang, N., Zhang, Y., Miao, L.-F., Ji, W., Wu, L., Liu, Y., Zhang, C.-Y., et al. (2021) · International Journal of Cardiology · doi:10.1016/j.ijcard.2021.02.025 · Cited by 49

Molecular fingerprints of cardiovascular toxicities of immune checkpoint inhibitors

Gergely, T. G., Drobni, Z. D., Sayour, N. V., Ferdinandy, P., & Varga, Z. V. (2024) · Basic Research in Cardiology · doi:10.1007/s00395-024-01068-8 · Cited by 54

Cardiotoxicities associated with immune checkpoint inhibitors

Yang, S., & Asnani, A. H. (2018) · Current Problems in Cancer · doi:10.1016/j.currproblcancer.2018.07.002 · Cited by 49

Myocarditis following the use of different immune checkpoint inhibitor regimens: A real-world analysis of post-marketing surveillance data

Fan, Q., Hu, Y., Yang, C., & Zhao, B. (2019) · International Immunopharmacology · doi:10.1016/j.intimp.2019.105866 · Cited by 49

Risk Factors for Immune Checkpoint Inhibitor–Mediated Cardiovascular Toxicities

Yousif, L. I., Screever, E. M., Versluis, D., Aboumsallem, J. P., Nierkens, S., Manintveld, O. C., de Boer, R. A., & Meijers, W. C. (2023) · Current Oncology Reports · doi:10.1007/s11912-023-01414-4 · Cited by 51

Opportunities and Challenges in Cardio-Oncology: A Bibliometric Analysis From 2010 to 2022

Shi, S., Lv, J., Chai, R., Xue, W., Xu, X., Zhang, B., Li, Y., Wu, H., Song, Q., & Hu, Y. (2022) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2022.101227 · Cited by 46

Conservative management of nivolumab-induced pericardial effusion: a case report and review of literature

Shaheen, S., Mirshahidi, H., Nagaraj, G., & Hsueh, C.-T. (2018) · Experimental Hematology and Oncology · doi:10.1186/s40164-018-0104-y · Cited by 45

Ipilimumab for the treatment of advanced melanoma in six kidney transplant patients

Zehou, O., Leibler, C., Arnault, J., Sayegh, J., Montaudié, H., Rémy, P., Glotz, D., Cordonnier, C., Martin, L., & Lebbé, C. (2018) · American Journal of Transplantation · doi:10.1111/ajt.15071 · Cited by 45

Clinical spectrum of neuromuscular complications after immune checkpoint inhibition

Puwanant, A., Isfort, M. C., Lacomis, D., & Živković, S. (2018) · Neuromuscular Disorders · doi:10.1016/j.nmd.2018.11.012 · Cited by 47

Prevention of Chemotherapy Induced Cardiomyopathy

Payne, D., & Nohria, A. (2017) · Current Heart Failure Reports · doi:10.1007/s11897-017-0353-9 · Cited by 44

Comparative Transcriptomics of Immune Checkpoint Inhibitor Myocarditis Identifies Guanylate Binding Protein 5 and 6 Dysregulation

Finke, D., Heckmann, M. B., Salatzki, J., Riffel, J. H., Herpel, E., Heinzerling, L., Meder, B., Völkers, M., Müller, O. J., Frey, N., et al. (2021) · Cancers · doi:10.3390/cancers13102498 · Cited by 44

Immune checkpoint inhibitor-induced myocarditis in cancer patients: a case report and review of reported cases

Matzen, E., Bartels, L. E., Løgstrup, B. B., Madsen, S. H., Stilling, C., & Donskov, F. N. (2021) · Cardio-Oncology · doi:10.1186/s40959-021-00114-x · Cited by 47

Cardiovascular Toxicity With PD-1/PD-L1 Inhibitors in Cancer Patients: A Systematic Review and Meta-Analysis

Liu, S., Gao, W., Ning, Y., Zou, X., Zhang, W., Zeng, L., & Liu, J. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.908173 · Cited by 46

Cancer therapy-induced cardiotoxicity: mechanisms and mitigations

Shil, S., Kumar, P., & Mumbrekar, K. D. (2025) · Heart Failure Reviews · doi:10.1007/s10741-025-10531-0 · Cited by 60

Genetics of cancer therapy-associated cardiotoxicity

Kim, Y., Seidman, J. G., & Seidman, C. E. (2022) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2022.03.010 · Cited by 45

A unique reason for coronary spasm causing temporary ST elevation myocardial infarction (inferior STEMI) – systemic inflammatory response syndrome after use of pembrolizumab

Nykl, R., Fischer, O., Vykoupil, K., & Táborský, M. (2017) · Archives of Medical Science - Atherosclerotic Diseases · doi:10.5114/amsad.2017.72531 · Cited by 41

Sequential Blockade of PD-1 and PD-L1 Causes Fulminant Cardiotoxicity—From Case Report to Mouse Model Validation

Liu, S., Huang, W., Yeh, H., Ko, C.-C., Shieh, H.-R., Hung, C., Chen, T.-Y., & Chen, Y.-J. (2019) · Cancers · doi:10.3390/cancers11040580 · Cited by 41

Cardiotoxicity with Immune System Targeting Drugs: A Meta-Analysis of Anti-PD/PD-L1 Immunotherapy Randomized Clinical Trials

Rahouma, M., Karim, N. A., Baudo, M., Yahia, M., Kamel, M., Eldessouki, I. A., Abouarab, A., Saad, I., Elmously, A., Gray, K. D., et al. (2019) · Immunotherapy · doi:10.2217/imt-2018-0118 · Cited by 43

Incidence of Pericardial Effusion in Patients with Advanced Non-Small Cell Lung Cancer Receiving Immunotherapy

Canale, M. L., Camerini, A., Casolo, G., Lilli, A., Bisceglia, I., Parrini, I., Lestuzzi, C., Meglio, J. D., PUCCETTI, C., Camerini, L., et al. (2020) · Advances in Therapy · doi:10.1007/s12325-020-01386-y · Cited by 40

Left ventricular myocardial strain and tissue characterization by cardiac magnetic resonance imaging in immune checkpoint inhibitor associated cardiotoxicity

Higgins, A. Y., Arbune, A., Soufer, A., Ragheb, E., Kwan, J. M., Lamy, J., Henry, M. L., Cuomo, J. R., Charifa, A., Gallegos, C., et al. (2021) · PLoS ONE · doi:10.1371/journal.pone.0246764 · Cited by 41

A Review of Immune-Mediated Adverse Events in Melanoma

Kennedy, L. B., & Salama, A. K. S. (2019) · Oncology and Therapy · doi:10.1007/s40487-019-0096-8 · Cited by 41

Complete Atrioventricular Block Associated with Pembrolizumab-induced Acute Myocarditis: The Need for Close Cardiac Monitoring

Katsume, Y., Isawa, T., Toi, Y., Fukuda, R., Kondo, Y., Sugawara, S., & Ootomo, T. (2018) · Internal Medicine · doi:10.2169/internalmedicine.0255-17 · Cited by 40

Myocarditis with checkpoint inhibitor immunotherapy: case report of late gadolinium enhancement on cardiac magnetic resonance with pathology correlate

Gallegos, C., Rottmann, D. A., Nguyen, V. Q., & Baldassarre, L. A. (2019) · European Heart Journal - Case Reports · doi:10.1093/ehjcr/yty149 · Cited by 40

Side effect management during immune checkpoint blockade using CTLA‐4 and PD‐1 antibodies for metastatic melanoma – an update

Kähler, K. C., Hassel, J. C., Heinzerling, L., Loquai, C., Thoms, K., Ugurel, S., Zimmer, L., & Gutzmer, R. (2020) · JDDG Journal der Deutschen Dermatologischen Gesellschaft · doi:10.1111/ddg.14128 · Cited by 39

Combined Effects of Electric Stimulation and Microgrooves in Cardiac Tissue‐on‐a‐Chip for Drug Screening

Ren, L. M., Zhou, X., Nasiri, R., Fang, J., Jiang, X., Wang, C., Qu, M., Ling, H., Chen, Y., Xue, Y., et al. (2020) · Small Methods · doi:10.1002/smtd.202000438 · Cited by 39

A retrospective study of immune checkpoint inhibitor-associated myocarditis in a single center in China

Wang, F., Sun, X., Qin, S., Hua, H., Liu, X., Yang, L., & Yang, M. (2020) · Chinese Clinical Oncology · doi:10.21037/cco.2020.03.08 · Cited by 39

Coronary Toxicities of Anti-PD-1 and Anti-PD-L1 Immunotherapies: a Case Report and Review of the Literature and International Registries

Ferreira, M., Pichon, É., Carmier, D., Bouquet, É., Pageot, C., Bejan‐Angoulvant, T., Campana, M., Vermès, E., & Marchand-Adam, S. (2018) · Targeted Oncology · doi:10.1007/s11523-018-0579-9 · Cited by 37

Therapeutic strategies for virus-negative myocarditis: a comprehensive review

Luca, G. D. D., Campochiaro, C., Sartorelli, S., Peretto, G., & Dagna, L. (2020) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2020.04.050 · Cited by 38

Immune checkpoint inhibitors-related myocarditis in patients with cancer: an analysis of international spontaneous reporting systems

Ma, R., Wang, Q., Meng, D., Li, K., & Zhang, Y. (2021) · BMC Cancer · doi:10.1186/s12885-020-07741-0 · Cited by 38

Stimulation of the PD-1 Pathway Decreases Atherosclerotic Lesion Development in Ldlr Deficient Mice

Grievink, H. W., Smit, V., Verwilligen, R. A. F., Kleijn, M. N. A. B., Smeets, D., Binder, C. J., Yagita∥, H., Moerland, M., Kuiper, J., Bot, I., et al. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.740531 · Cited by 36

BLT-Immune Humanized Mice as a Model for Nivolumab-Induced Immune-Mediated Adverse Events: Comparison of the NOG and NOG-EXL Strains

Weaver, J. L., Zadrozny, L. M., Gabrielson, K. L., Semple, K. M., Shea, K. I., & Howard, K. E. (2019) · Toxicological Sciences · doi:10.1093/toxsci/kfz045 · Cited by 35

The incidence and risk of cardiovascular events associated with immune checkpoint inhibitors in Asian populations

Chiang, C., Chiang, C., Sheng‐Kai, K., Hsia, Y. P., Lee, Y.-W., Wu, H., Chiang, C., Peng, C.-Y., Wei, J. C., Shiah, H., et al. (2022) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyac150 · Cited by 37

Betulin silver nanoparticles qualify as efficient antimelanoma agents in in vitro and in vivo studies

Danciu, C., Pînzaru, I., Coricovac, D. E., Andrica, F., Sizemore, I. E. P., Dehelean, C. A., Baderca, F., Lăzureanu, V. E., Şoica, C., Mioc, M., et al. (2018) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2018.11.006 · Cited by 34

Tofacitinib for treatment in immune-mediated myocarditis: The first reported cases

Liu, Y., & Jiang, L. (2020) · Journal of Oncology Pharmacy Practice · doi:10.1177/1078155220947141 · Cited by 35

Pericardial Toxicities Associated With Immune Checkpoint Inhibitors: A Pharmacovigilance Analysis of the FDA Adverse Event Reporting System (FAERS) Database

Ma, Z., Pei, J., Sun, X., Liu, L., Lu, W., Guo, Q., Lyu, J., Liu, Y., Zhang, Y., & Zhao, Z. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.663088 · Cited by 37

Design of short peptides to block BTLA/HVEM interactions for promoting anticancer T-cell responses

Spodzieja, M., Lach, S., Iwaszkiewicz, J., Cesson, V., Kalejta, K., Olive, D., Michielin, O. A., Speiser, D. E., Zoete, V., Derré, L., et al. (2017) · PLoS ONE · doi:10.1371/journal.pone.0179201 · Cited by 34

Pre‐treatment high‐sensitivity troponin T for the short‐term prediction of cardiac outcomes in patients on immune checkpoint inhibitors

Petricciuolo, S., Donne, M. G. D., Aimo, A., Chella, A., & Caterina, R. D. (2020) · European Journal of Clinical Investigation · doi:10.1111/eci.13400 · Cited by 34

Myocarditis related to immune checkpoint inhibitors treatment: two case reports and literature review

Chen, Y., Jia, Y., Liu, Q., Shen, Y., Zhu, H., Dong, X., Huang, J., Lu, J., & Yin, Q. (2021) · Annals of Palliative Medicine · doi:10.21037/apm-20-2620 · Cited by 33

Role of the Immune System Elements in Pulmonary Arterial Hypertension

Tomaszewski, M., Bębnowska, D., Hrynkiewicz, R., Dworzyński, J., Niedźwiedzka‐Rystwej, P., Kopeć, G., & Grywalska, E. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10163757 · Cited by 33

Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: Current Progresses and Challenges

Liu, H.-T., Jiang, M., Deng, Z., Li, L., Huang, J.-L., Liu, Z., Li, L., & Zhong, J. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.737497 · Cited by 34

Re-introducing immunotherapy in patients surviving immune checkpoint inhibitors-mediated myocarditis

Hasson, S. P., Salwen, B., Sivan, A., Shamai, S., Geva, R., Merimsky, O., Raphael, A., Shmilovich, H., Moshkovits, Y., Kapusta, L., et al. (2020) · Clinical Research in Cardiology · doi:10.1007/s00392-020-01648-3 · Cited by 32

Identification of an immune overdrive high-risk subpopulation with aberrant expression of FOXP3 and CTLA4 in colorectal cancer

Cui, K., Yao, S., Zhang, H., Zhou, M., Liu, B., Cao, Y., Fei, B., Huang, S., & Huang, Z. (2021) · Oncogene · doi:10.1038/s41388-021-01677-w · Cited by 32

Risk of Cardiac Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Regimens: A Systematic Review and Meta-Analysis

Hu, J., Tian, R., Ma, Y., Zhen, H., Ma, X., Su, Q., & Cao, B. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.645245 · Cited by 31

Advances and challenges in immunotherapy of small cell lung cancer

Guo, H., Li, L., & Cui, J. (2020) · Chinese Journal of Cancer Research · doi:10.21147/j.issn.1000-9604.2020.01.13 · Cited by 30

Severe combined cardiac and neuromuscular toxicity from immune checkpoint blockade: an institutional case series

Arora, P. C., Talamo, L., Dillon, P. M., Gentzler, R. D., Millard, T. A., Salerno, M., Slingluff, C. L., & Gaughan, E. M. (2020) · Cardio-Oncology · doi:10.1186/s40959-020-00076-6 · Cited by 30

Pomalidomide Inhibits PD-L1 Induction to Promote Antitumor Immunity

Fujiwara, Y., Sun, Y., Torphy, R. J., He, J., Yanaga, K. K., Edil, B. H., Schulick, R. D., & Zhu, Y. (2018) · Cancer Research · doi:10.1158/0008-5472.can-18-1781 · Cited by 30

Cardiotoxicity of Novel Targeted Chemotherapeutic Agents

Rhea, I. B., & Oliveira, G. H. (2018) · Current Treatment Options in Cardiovascular Medicine · doi:10.1007/s11936-018-0649-4 · Cited by 28

Cardiac toxicities of anticancer treatments

Zarifa, A., Albittar, A. A., Kim, P. Y., Hassan, S. A., Palaskas, N. L., Iliescu, C., Durand, J., & Lopez‐Mattei, J. (2019) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000000641 · Cited by 31

Precision Cardio-Oncology: a Systems-Based Perspective on Cardiotoxicity of Tyrosine Kinase Inhibitors and Immune Checkpoint Inhibitors

Brown, S.-A. N., Ray, J. C., & Herrmann, J. (2020) · Journal of Cardiovascular Translational Research · doi:10.1007/s12265-020-09992-5 · Cited by 29

Cancer immunotherapy: A comprehensive appraisal of its modes of application (Review)

Hoteit, M., Oneissi, Z., Reda, R., Wakim, F., Zaidan, A., Farran, M., Khalil, E. A., & El‐Sibai, M. (2021) · Oncology Letters · doi:10.3892/ol.2021.12916 · Cited by 32

Dark Side of Cancer Therapy: Cancer Treatment-Induced Cardiopulmonary Inflammation, Fibrosis, and Immune Modulation

Boopathi, E., & Thangavel, C. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221810126 · Cited by 29

Exploring the Mechanisms Underlying the Cardiotoxic Effects of Immune Checkpoint Inhibitor Therapies

Ronen, D., Bsoul, A., Lotem, M., Abedat, S., Yarkoni, M., Amir, O., & Asleh, R. (2022) · Vaccines · doi:10.3390/vaccines10040540 · Cited by 29

PD-1/PD-L1 Inhibitor-Associated Myocarditis: Epidemiology, Characteristics, Diagnosis, Treatment, and Potential Mechanism

Dong, H., Qi, Y., Kong, X., Wang, Z., Fang, Y., & Wang, J. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.835510 · Cited by 28

Nanomedicine: A pragmatic approach for tackling melanoma skin cancer

Prajapat, V. M., Mahajan, S., Paul, P., Aalhate, M., Mehandole, A., Madan, J., Dua, K., Chellappan, D. K., Singh, S. K., & Singh, P. K. (2023) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2023.104394 · Cited by 28

Nebenwirkungsmanagement bei Immun‐Checkpoint‐Blockade durch CTLA‐4‐ und PD‐1‐Antikörper beim metastasierten Melanom – ein Update

Kähler, K. C., Hassel, J. C., Heinzerling, L., Loquai, C., Thoms, K., Ugurel, S., Zimmer, L., Gutzmer, R., & (ADO), F. D. K. „. N. D. A. D. O. (2020) · JDDG Journal der Deutschen Dermatologischen Gesellschaft · doi:10.1111/ddg.14128_g · Cited by 27

Potential cardiac risk of immune‐checkpoint blockade as anticancer treatment: What we know, what we do not know, and what we can do to prevent adverse effects

Spallarossa, P., Meliota, G., Brunelli, C., Arboscello, E., Ameri, P., Dessalvi, C. C., Grossi, F., Deidda, M., Mele, D., Sarocchi, M., et al. (2017) · Medicinal Research Reviews · doi:10.1002/med.21478 · Cited by 27

Myocardial and Pericardial Toxicity Associated With Immune Checkpoint Inhibitors in Cancer Patients

Chahine, J., Collier, P. H., Maroo, A. P., Tang, W. H. W., & Klein, A. L. (2020) · JACC Case Reports · doi:10.1016/j.jaccas.2019.11.080 · Cited by 27

Cardiotoxicity in cancer immune-checkpoint therapy: Mechanisms, clinical evidence, and management strategies

Sun, J.-Y., Qu, Q., Lou, Y.-X., Yang, H., Sun, G.-Z., Sun, W., & Kong, X. (2021) · International Journal of Cardiology · doi:10.1016/j.ijcard.2021.09.041 · Cited by 27

Immune checkpoint-associated cardiotoxicity: case report with systematic review of literature

Chauhan, A., Burkeen, G., Houranieh, J., Arnold, S. M., & Anthony, L. B. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx213 · Cited by 27

New drugs and new toxicities: pembrolizumab-induced myocarditis

Inayat, F., Masab, M., Gupta, S., & Ullah, W. (2018) · BMJ Case Reports · doi:10.1136/bcr-2017-223252 · Cited by 27

Pediatric Cardio-Oncology: Development of Cancer Treatment-Related Cardiotoxicity and the Therapeutic Approach to Affected Patients

Ryan, T. D., Nagarajan, R., & Godown, J. A. (2019) · Current Treatment Options in Oncology · doi:10.1007/s11864-019-0658-x · Cited by 27

Optimized monitoring for immune checkpoint inhibitor induced myocarditis using high-sensitivity troponin-T

Tomsitz, D., Grabmaier, U., Spiro, J., Nicolai, L., French, L. E., Maßberg, S., & Heinzerling, L. (2024) · European Journal of Cancer · doi:10.1016/j.ejca.2024.115186 · Cited by 26

Cardiac Toxicity Associated with Cancer Immunotherapy and Biological Drugs

Montisci, A., Vietri, M. T., Palmieri, V., Sala, S., Donatelli, F., & Claudio Napoli, A. (2021) · Cancers · doi:10.3390/cancers13194797 · Cited by 27

Advances in immune checkpoint inhibitors induced-cardiotoxicity

Li, X., Peng, W., Wu, J., Yeung, S. J., & Yang, R. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1130438 · Cited by 28

Initial experience of anti-PD1 therapy with nivolumab in advanced hepatocellular carcinoma

Duan, F., Hui, X., Lu, S., Bai, Y.-H., Cui, L., Li, X., & Jieyu, Y. (2017) · Oncotarget · doi:10.18632/oncotarget.20029 · Cited by 26

Cardiac Immune-Related Adverse Events in Immune Checkpoint Inhibition Therapy

Brumbaugh, A. D., Narurkar, R., Parikh, K., Fanucchi, M. P., & Frishman, W. H. (2018) · Cardiology in Review · doi:10.1097/crd.0000000000000217 · Cited by 25

A review of immune checkpoint inhibitor-associated myocarditis: Epidemiology, pathogenesis, and biomarkers

Xu, L., Chen, Y., Xiong, L., Shen, Y., Zhou, Z., Wang, S., & Xu, X. (2025) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2025.2512645 · Cited by 32

Cardiotoxicity of immune checkpoint inhibitors

Varricchi, G., Galdiero, M. R., Marone, G., Criscuolo, G., Triassi, M., Bonaduce, D., Marone, G., & Tocchetti, C. G. (2017) · ESMO Open · doi:10.1136/esmoopen-2017-000247 · Cited by 247

Immune Checkpoint Inhibitors and Cardiac Toxicity: An Emerging Issue

Varricchi, G., Marone, G., Mercurio, V., Galdiero, M. R., Bonaduce, D., & Tocchetti, C. G. (2017) · Current Medicinal Chemistry · doi:10.2174/0929867324666170407125017 · Cited by 117

Cardiac Toxicity Associated with Immune Checkpoint Inhibitors: A Systematic Review

Shalata, W., Abu-Salman, A., Steckbeck, R., Jacob, B. M., Massalha, I., & Yakobson, A. (2021) · Cancers · doi:10.3390/cancers13205218 · Cited by 109

Cancer immune checkpoint blockade therapy and its associated autoimmune cardiotoxicity

Zhang, J.-C., Chen, W., Alvarez, J. B., Jia, K. Q., Shi, L., Wang, Q., Zou, N., He, K., & Zhu, H. (2018) · Acta Pharmacologica Sinica · doi:10.1038/s41401-018-0062-2 · Cited by 54

Cardiac Toxicities of Immune Checkpoint Inhibitors: MoreAwareness is Needed

Nicolas, J., & Nicolas, J. (2024) · Journal of Cardiology Research Review & Reports · doi:10.47363/jcrrr/2024(5)196